DDT exposure linked to Alzheimer's

19 February 2014

A study by UT Southwestern Medical Center has found that exposure to DDT may lead to Alzheimer’s disease later in life.

The study, published in the journal JAMA Neurology, found elevated levels of the DDT metabolite, DDE, that were 3.8 times higher in patients diagnosed with Alzheimer’s disease in comparison to control subjects.

Previous studies have linked chronic diseases such as cancer and diabetes to DDT, but this is the first clinical study to link the pesticide to Alzheimer’s disease. Alzheimer’s disease is the most common neurodegenerative disease worldwide and is expected to increase three-fold over the next 40 years, according to the researchers.

These findings may help lead to the development of early biomarkers that can determine whether a person will develop Alzheimer’s disease later in life due to DDT exposure.

Researchers made the link between DDE and Alzheimer’s by measuring three components – blood serum levels, severity of the patient’s Alzheimer’s disease as measured by the Mini-Mental State Examination (MMSE) and its relation to serum DDE levels, and the reaction of isolated nerve cells to DDE. Treatment of human nerve cells with DDE caused them to increase the production of the amyloid precursor protein that is directly linked to Alzheimer’s disease.

DDT (dichloro-diphenyl-trichloroethane) was used extensively as an insecticide in the 1940s, but has been banned in the United States since 1972 after scientists linked the compound to wildlife health and environmental concerns. DDT is still used in other countries to combat the spread of malaria.

“We have additional studies underway that will seek to directly link DDT exposure to Alzheimer’s disease,” said co-author Dr. Dwight German, Professor of Psychiatry at UT Southwestern. “If a direct link is made, our hope is to then identify the presence of DDE in blood samples from people at an early age and administer treatments to remove it.”

The studies were conducted in partnership with researchers at Emory University School of Medicine and Rutgers Robert Wood Johnson Medical School. Participants in the study underwent preliminary testing to ensure that they didn’t have symptoms of other dementia-related diseases, and were an average age of 74, while the control subjects were on average 70 years old. The study found elevated levels of DDE in blood samples of 86 patients with Alzheimer’s disease as compared to 79 control patients from the UT Southwestern Alzheimer’s Disease Center and the Emory University Alzheimer’s Disease Center.

 

To top